Join Us: Upstate New York Hematology & Hematologic Oncology Conference: Updates from the 65th ASH Annual Meeting


This CME-accredited activity, the Upstate New York Hematology & Hematologic Oncology Conference: Updates from the 65th ASH Annual Meeting, is a two-day symposium designed to provide an engaging and interactive forum for discussing the latest breakthroughs in benign and malignant hematology. The conference will feature lectures and panel discussions by regional experts from the Upstate New York region and invited nationally recognized experts from leading institutions across the United States. This symposium will offer in-depth coverage of the entire spectrum of malignant hematology topics, including lymphoid, myeloid, and plasma cell neoplasms, as well as benign hematology topics and considerations for special populations. This activity aims to improve knowledge and advance the ability of hematology oncology providers to apply current and emerging treatment strategies in managing benign and malignant blood disorders to improve patient outcomes.

Expert faculty will contextualize potentially practice-changing research, including the abstracts presented at the 65th ASH Annual Meeting in December 2023 (ASH23), and discuss how the results may alter the current standard of care. This conference will emphasize a multidisciplinary approach and the integration of new advances into patient-centered care.



Click here to learn more or register now

Nivolumab Associated With Higher Progression-Free Survival in Pediatric Advanced-Stage Hodgkin Lymphoma

Replacing brentuximab vedotin with nivolumab in first-line treatment combined with the chemotherapy regimen AVD improved progression-free survival in pediatric patients with newly diagnosed, advanced-stage classic Hodgkin lymphoma (cHL), ...

Roswell Park’s Chief of Myeloma Delivers Updated Clinical Trial Data at American Society of Hematology Annual Meeting

A single infusion of the CAR T cell therapy ciltacabtagene autoleucel produced deep, durable responses in multiple myeloma patients whose disease had progressed less than a year after autologous stem cell transplant (ASCT) or who experienced ...